公开(公告)号：US20170035877A1

公开(公告)日：2017-02-09

申请号：US14508369

申请日：2014-10-07

Applicant: International AIDS Vaccine Initiative ,  The Scripps Research Institute

Inventor： Richard Wyatt ,  Andrew Ward ,  Karen Tran ,  Shailendra Kumar ,  Jidnyasa Ingale ,  Javier Guenaga ,  Yu Feng ,  Viktoria Dubrowskaya ,  Natalia de Val Alta

IPC: A61K39/21 ,  C07K14/005 ,  C12N7/00

CPC classification number: A61K39/21 ,  A61K39/12 ,  A61K2039/55505 ,  A61K2039/55555 ,  A61K2039/645 ,  C07K14/005 ,  C07K14/162 ,  C12N7/00 ,  C12N2740/16022 ,  C12N2740/16034 ,  C12N2740/16122 ,  C12N2740/16134

Abstract: The present application relates to novel HIV-1 envelope glycoproteins which may be utilized as an HIV-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.

Abstract translation: 本申请涉及可用作HIV-1疫苗免疫原的新型HIV-1包膜糖蛋白，用于结晶的抗原和用于鉴定广泛的中和抗体。 本发明包括配制成本发明疫苗的免疫原性组合物的制备和纯化。

公开(公告)号：US20160367659A1

公开(公告)日：2016-12-22

申请号：US15104249

申请日：2014-12-19

Applicant: EQUIGERMINAL SA

Inventor： Isabel Maria Fidalgo dos Santos Silva CARVALHO ,  Alexandre Simao Vieira PIRES

IPC: A61K39/21 ,  G01N33/569

CPC classification number: A61K39/21 ,  A61K39/12 ,  A61K2039/55522 ,  C12N2740/15022 ,  C12N2740/15034 ,  G01N33/56983 ,  G01N2333/155 ,  G01N2469/20

Abstract: A composition comprising one or more peptides selected from the group consisting of SEQ ID NOs 1 to 76; and/or comprising one or more polynucleotide sequences encoding one or more of the peptides selected from the group consisting of SEQ ID NOs 1 to 76; and/or comprising one or more polynucleotide sequences selected from the group consisting of SEQ ID NOs 77 to 152.

Abstract translation: 一种组合物，其包含一种或多种选自SEQ ID NO：1至76的肽; 和/或包含一种或多种编码一种或多种选自SEQ ID NO：1至76的肽的多核苷酸序列; 和/或包含一个或多个选自SEQ ID NO：77至152的多核苷酸序列。

公开(公告)号：US20160354461A1

公开(公告)日：2016-12-08

申请号：US15092024

申请日：2016-04-06

Applicant: Oregon Health & Science University

Inventor： Louis J. Picker ,  Michael A. Jarvis ,  Jay A. Nelson

IPC: A61K39/21 ,  C12N7/00 ,  C12N15/86 ,  C07K14/005

CPC classification number: A61K39/21 ,  A61K39/04 ,  A61K39/12 ,  A61K48/00 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/572 ,  C07K14/005 ,  C07K16/088 ,  C07K2319/00 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/16134 ,  C12N2710/16143 ,  C12N2740/15022 ,  C12N2740/15034 ,  C12N2740/16034 ,  C12N2740/16134 ,  C12N2740/16234 ,  C12N2740/16334 ,  C12N2800/30 ,  C12N2830/003

Abstract: Particular aspects provide for use of the β-herpesvirus Cytomegalovirus (CMV: e.g., RhCMV and HCMV) as a uniquely evolved “vector” for safely initiating and indefinitely maintaining high level cellular and humoral immune responses (against, e.g., HIV, SIV, TB, etc.). Particular aspects provide a method for treatment or prevention of, e.g., HIV, SIV or TB, comprising infection of a subject in need thereof with at least one recombinant CMV-based vector (e.g., HCMV or RhCMV) comprising an expressible HIV/SIV/TB antigen or a variant or fusion protein thereof. In particular embodiments of the method, infection is of an immunocompetent, HCMV or RhCMV seropositive subject. Additional aspects provide for RhCMV- and HCMV-based vaccine vectors, and versions thereof with suicide or safety means. Further aspects provide pharmaceutical compositions comprising the inventive CMV-based vaccine vectors.

Abstract translation: 特定方面提供使用β-疱疹病毒巨细胞病毒（CMV：例如RhCMV和HCMV）作为独特演化的“载体”，用于安全地启动和无限期维持高水平的细胞和体液免疫应答（例如，HIV，SIV，TB 等）。 具体方面提供了用于治疗或预防例如HIV，SIV或TB的方法，其包括用至少一种基于重组CMV的载体（例如，HCMV或RhCMV）感染有需要的受试者，所述载体包含可表达的HIV / SIV / TB抗原或其变体或融合蛋白。 在该方法的具体实施方案中，感染是免疫活性的，HCMV或RhCMV血清阳性受试者。 其他方面提供基于RhCMV和HCMV的疫苗载体，以及具有自杀或安全手段的版本。 其它方面提供包含本发明的基于CMV的疫苗载体的药物组合物。

公开(公告)号：US09511136B2

公开(公告)日：2016-12-06

申请号：US14404254

申请日：2013-05-30

Applicant: INNAVIRVAX

Inventor： Joël Crouzet ,  Raphaël Ho Tsong Fang ,  Dominique Desfontaines

IPC: A61K39/21 ,  A61K39/12 ,  A61K47/48 ,  A61K39/00 ,  C07K16/10 ,  C12N7/00

CPC classification number: A61K39/21 ,  A61K39/12 ,  A61K47/6415 ,  A61K2039/53 ,  A61K2039/55505 ,  A61K2039/6037 ,  A61K2039/6081 ,  A61K2039/627 ,  C07K16/1063 ,  C12N7/00 ,  C12N2740/16134

Abstract: The present invention relates to the field of vaccines directed against viruses of the HIV family. More particularly, it relates to an immunogenic compound comprising a peptide of the following formula (I) NH2-[Nt]y-P-W-N-X-S-X2-S-N-X3-X4-X-X6-X7-I-W-[Ct]z-COOH (I) which is covalently linked to a carrier protein consisting of a CRM197 protein. It also concerns a composition containing this immunogenic compound and the uses of these immunogenic compounds and compositions for preventing and/or treating a condition caused by the infection of an individual with a HIV virus.

Abstract translation: 本发明涉及针对HIV家族病毒的疫苗领域。 更具体地，本发明涉及包含下式（I）的肽的免疫原性化合物：NH 2 - [Nt] yPWNXS-X2-SN-X3-X4-X-X6-X7-IW- [Ct] z-COOH ），其与由CRM197蛋白质组成的载体蛋白共价连接。 它还涉及含有该免疫原性化合物的组合物以及这些免疫原性化合物和组合物用于预防和/或治疗由HIV病毒感染个体引起的病症的用途。

公开(公告)号：US09499589B2

公开(公告)日：2016-11-22

申请号：US13897319

申请日：2013-05-17

Applicant: The Johns Hopkins University

Inventor： Thomas August ,  Ernesto Marques, Jr.

IPC: C07K14/00 ,  C07K14/005 ,  A61K39/21 ,  C07H21/04 ,  C12N15/62 ,  C12N15/86 ,  A61K39/12 ,  A61K39/00 ,  C07K14/705

CPC classification number: A61K39/21 ,  A61K39/00 ,  A61K39/12 ,  A61K2039/53 ,  A61K2039/57 ,  C07H21/04 ,  C07K14/005 ,  C07K14/70596 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/06 ,  C07K2319/40 ,  C12N7/00 ,  C12N15/62 ,  C12N15/86 ,  C12N2740/16234 ,  C12N2750/14143

Abstract: The invention provides chimeric proteins and nucleic acids encoding these which can be used to generate vaccines against selected antigens. In one aspect, a chimeric protein comprises an antigen sequence and a domain for trafficking the protein to an endosomal compartment, irrespective of whether the antigen is derived from a membrane or non-membrane protein. In one preferred aspect, the trafficking domain comprises a lumenal domain of a LAMP polypeptide. Alternatively, or additionally, the chimeric protein comprises a trafficking domain of an endocytic receptor (e.g., such as DEC-205 or gp200-MR6). The vaccines (DNA, RNA or protein) can be used to modulate or enhance an immune response against any kind of antigen. In one preferred aspect, the invention provides a method for treating a patient with cancer by providing a chimeric protein comprising a cancer-specific antigen or a nucleic acid encoding the protein to the patient.

公开(公告)号：US09464131B2

公开(公告)日：2016-10-11

申请号：US13780776

申请日：2013-02-28

Applicant: Theraclone Sciences, Inc. ,  The Scripps Research Institute ,  International AIDS Vaccine Initiative

Inventor： Po-Ying Chan-Hui ,  Katherine Doores ,  Michael Huber ,  Stephen Kaminsky ,  Steven Frey ,  Ole Olsen ,  Jennifer Mitcham ,  Matthew Moyle ,  Sanjay K. Phogat ,  Dennis R. Burton ,  Laura Marjorie Walker ,  Pascal Raymond Georges Poignard ,  Wayne Koff ,  Melissa Danielle De Jean De St. Marcel Simek-Lemos

IPC: C07K16/10 ,  A61K39/21 ,  A61K39/00

CPC classification number: C07K16/1063 ,  A61K39/21 ,  A61K2039/505 ,  C07K16/1045 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.

Abstract translation: 本发明提供一种获得广泛中和抗体（bNab）的方法，包括筛选来自供体PBMC样品的记忆B细胞培养物，以对多种HIV-1物质进行中和活性，克隆显示广泛中和活性的记忆B细胞; 并从该记忆B细胞培养物中拯救单克隆抗体。 所得到的单克隆抗体的特征在于它们以天然或单体形式选择性地结合来自Env蛋白的表位的能力，以及抑制HIV-1物种从多个进化枝的感染的能力。 提供了含有用于预防，诊断和治疗HIV感染的人单克隆抗HIV抗体的组合物。 提供了通过使用来自gp120的可变环内的保守区域的表位进行免疫来产生这种抗体的方法。 还提供了产生抗艾滋病毒1型免疫球蛋白的免疫原。 此外，提供了使用合适表位的疫苗接种方法。

公开(公告)号：US09446117B2

公开(公告)日：2016-09-20

申请号：US13767569

申请日：2013-02-14

Applicant: Russell F. Bey ,  Randy S Simonson ,  Kamesh Reddy Sirigireddy ,  Benjamin Matthew Hause

Inventor： Russell F. Bey ,  Randy S Simonson ,  Kamesh Reddy Sirigireddy ,  Benjamin Matthew Hause

IPC: A61K39/15 ,  A61K39/12 ,  A61K39/21 ,  C07K16/10 ,  C07K14/005 ,  A61K39/00 ,  A61K38/00

CPC classification number: A61K39/15 ,  A61K38/00 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/5258 ,  A61K2039/545 ,  A61K2039/552 ,  A61K2039/55505 ,  A61K2039/55566 ,  A61K2039/55577 ,  A61K2039/70 ,  C07K14/005 ,  C07K16/10 ,  C07K2319/00 ,  C12N2720/12334

Abstract: The present invention provides Rotavirus antigenic polypeptides or antigens that elicit an immune response in animal or human against rotavirus, compositions comprising said rotavirus polypeptides, methods of vaccination against rotavirus, and kits for use with such methods and compositions. The invention further provide novel expression vectors for producing the vaccine antigenic polypeptides.

Abstract translation: 本发明提供了轮状病毒抗原性多肽或抗原，其在动物或人体中引起针对轮状病毒的免疫应答，包含所述轮状病毒多肽的组合物，针对轮状病毒的疫苗接种方法，以及用于此类方法和组合物的试剂盒。 本发明还提供了用于产生疫苗抗原多肽的新型表达载体。

公开(公告)号：US09446107B2

公开(公告)日：2016-09-20

申请号：US14750423

申请日：2015-06-25

Applicant: President and Fellows of Harvard College ,  Regents of the University of Michigan

Inventor： David J. Mooney ,  Omar Abdel-Rahman Ali ,  Eduardo Alexandre Barros E Silva ,  Hyun Joon Kong ,  Elliot Earl Hill, Jr. ,  Tanyarut Boontheekul

IPC: A61K39/00 ,  A61L27/56 ,  A61L27/18 ,  A61K38/19 ,  A61L27/58 ,  A61L27/54 ,  A61L27/36 ,  A61L27/38

CPC classification number: A61K39/0011 ,  A61K9/0024 ,  A61K9/1647 ,  A61K38/1866 ,  A61K38/193 ,  A61K38/39 ,  A61K39/21 ,  A61K39/39 ,  A61K2039/54 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55561 ,  A61K2039/55583 ,  A61K2039/6093 ,  A61L27/18 ,  A61L27/20 ,  A61L27/3633 ,  A61L27/38 ,  A61L27/3826 ,  A61L27/54 ,  A61L27/56 ,  A61L27/58 ,  A61L2300/232 ,  A61L2300/252 ,  A61L2300/412 ,  A61L2300/414 ,  A61L2300/426 ,  A61L2300/438 ,  A61L2300/604 ,  A61L2300/606 ,  A61L2400/18 ,  A61L2430/30 ,  A61L2430/34 ,  B33Y80/00 ,  C12N7/00 ,  C12N15/117 ,  C12N2310/17 ,  C12N2320/32 ,  C12N2740/16034 ,  Y02A50/411

Abstract: A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated into or coated onto the scaffold composition such that the scaffold composition and/or a bioactive composition controls egress of a resident cell or progeny thereof. The devices mediate active recruitment, modification, and release of host cells from the material.

公开(公告)号：US09441247B2

公开(公告)日：2016-09-13

申请号：US14792247

申请日：2015-07-06

Applicant: AlphaVax, Inc.

Inventor： Jon O. Rayner ,  Jonathan F. Smith ,  Bolyn Hubby ,  Elizabeth A. Reap

IPC: C12N15/86 ,  A61K39/21 ,  C07K14/005 ,  C12N7/00 ,  A61K39/12 ,  A61K48/00 ,  A61K39/00

CPC classification number: C12N15/86 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/21 ,  A61K48/00 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/575 ,  C07K14/005 ,  C12N7/00 ,  C12N2740/16222 ,  C12N2740/16234 ,  C12N2770/36123 ,  C12N2770/36134 ,  C12N2770/36143 ,  C12N2770/36152 ,  C12N2770/36162 ,  C12N2840/203

Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.

公开(公告)号：US20160250309A1

公开(公告)日：2016-09-01

申请号：US15006923

申请日：2016-01-26

Applicant: University Health Network

Inventor： Jeffrey A. Medin ,  Andrea McCart ,  Severine Loisel

IPC: A61K39/00 ,  A61K48/00 ,  C12N15/86 ,  C07K14/54 ,  C07K14/705 ,  C12N7/00 ,  A61K38/20

CPC classification number: A61K39/0011 ,  A01K67/0275 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2227/105 ,  A01K2267/0331 ,  A61K38/208 ,  A61K39/21 ,  A61K48/005 ,  A61K2039/5154 ,  A61K2039/5156 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/55522 ,  A61K2039/55538 ,  A61K2039/57 ,  A61K2039/575 ,  C07K14/5434 ,  C07K14/70503 ,  C07K2319/06 ,  C12N7/00 ,  C12N15/8509 ,  C12N15/86 ,  C12N2740/15021 ,  C12N2740/15034 ,  C12N2740/15043 ,  C12N2740/15071 ,  C12N2740/16043

Abstract: Compositions and methods for delivering tumor associated antigens and immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as colon cancer.

Abstract translation: 公开了用于递送肿瘤相关抗原和免疫调节分子以产生治疗效果的组合物和方法。 组合物和方法使用稳定整合的慢病毒递送系统。 该方法可用于治疗和预防性治疗诸如结肠癌的癌症。